Rybelsus N 1.5 mg
Rybelsus N 1.5 mg is a medicine authorised by Swissmedic under authorisation number 69865. The authorisation holder is Novo Nordisk Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 28 November 2025 and the authorisation is limited until 27 November 2030. ATC code A10BJ06 places the medicine in the group Drugs used in diabetes.
| Authorisation number | 69865 |
|---|---|
| Name | Rybelsus N 1.5 mg |
| Full name | Rybelsus N 1.5 mg, Tabletten |
| Authorisation holder | Novo Nordisk Pharma AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | B · Prescription only |
| ATC code | A10BJ06 |
| First authorisation | 28 November 2025 |
| Authorisation validity | 27 November 2030 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Rybelsus N 1.5 mg, Tabletten | B | 28 November 2025 |
| 2 | Rybelsus N 4 mg, Tabletten | B | 28 November 2025 |
| 3 | Rybelsus N 9 mg, Tabletten | B | 28 November 2025 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 30 | Tablette(n) | A10BJ06 | 07.06.2. | B |
| 2 | 30 | Tablette(n) | A10BJ06 | 07.06.2. | B |
| 3 | 90 | Tablette(n) | A10BJ06 | 07.06.2. | B |
| 4 | 30 | Tablette(n) | A10BJ06 | 07.06.2. | B |
| 5 | 90 | Tablette(n) | A10BJ06 | 07.06.2. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Rybelsus N 1.5 mg authorised in Switzerland?
Yes. Rybelsus N 1.5 mg is authorised by Swissmedic under authorisation number 69865, data as of 01 September 2026. The authorisation is limited until 27 November 2030.
Which dispensing category does Rybelsus N 1.5 mg have?
Rybelsus N 1.5 mg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Rybelsus N 1.5 mg?
The authorisation holder is Novo Nordisk Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.